How US Can Learn From Biosimilar Implementation In EU
This article was originally published in The Pink Sheet Daily
Executive Summary
Differences in payer policies have limited the biosimilar opportunity in some EU nations; IMS report points to examples US should replicate or avoid as biosimilars are introduced domestically.